Sugi Predict

Sugi Predict / Targets / HDAC7

HDAC7

Histone deacetylase 7 · Q8WUI4 · HDAC7 on Sugi Atlas →

361,024 patent compounds predicted against HDAC7, 236,747 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL28250 SCHEMBL28250 0.57 14/20
SCHEMBL29476 SCHEMBL29476 0.57 14/20
SCHEMBL31064 SCHEMBL31064 0.57 14/20
SCHEMBL30259 SCHEMBL30259 0.57 14/20
SCHEMBL28328 SCHEMBL28328 0.61 13/20
SCHEMBL28329 SCHEMBL28329 0.61 13/20
SCHEMBL28330 SCHEMBL28330 0.61 13/20
SCHEMBL29695 SCHEMBL29695 0.61 13/20
SCHEMBL30199 SCHEMBL30199 0.61 13/20
Vorinostat Vorinostat (SCHEMBL9018) 1.00 12/20
Iodipamide Iodipamide (SCHEMBL37678) 0.41 12/20
Trichostatin Trichostatin (SCHEMBL19886) 1.00 10/20
SCHEMBL34229 SCHEMBL34229 0.51 10/20
SCHEMBL19539 SCHEMBL19539 0.48 10/20
SCHEMBL28840 SCHEMBL28840 0.61 9/20
SCHEMBL28841 SCHEMBL28841 0.61 9/20
SCHEMBL28842 SCHEMBL28842 0.61 9/20
SCHEMBL29955 SCHEMBL29955 0.61 9/20
SCHEMBL29956 SCHEMBL29956 0.61 9/20
SCHEMBL21138 SCHEMBL21138 0.49 9/20

Clinical trials — most relevant to HDAC7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Chidamide Combined With Toripalimab in Sarcoma PHASE2COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma PHASE2COMPLETED
Voronistat in Pediatric Patients With Drug Resistant Epilepsy PHASE2UNKNOWN
Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART PHASE1/PHASE2COMPLETED
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
Vorinostat in Children PHASE1/PHASE2COMPLETED
Research In Viral Eradication of HIV Reservoirs PHASE2COMPLETED
Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma PHASE2RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors PHASE2COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors PHASE1COMPLETED
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers PHASE1COMPLETED
Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment PHASE1ACTIVE_NOT_RECRUITING
Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors PHASE1COMPLETED
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction PHASE1COMPLETED
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome nanUNKNOWN
Chi-GVM Regimen for the Treatment of R/R PTCL nanUNKNOWN
Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study nanWITHDRAWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia nanRECRUITING
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a HDAC7 binder may also engage these)

ProteinNameSimilarity
Q8C2B3 — 0.998 Q8C2B3 →
Q8K330 — 0.992 Q8K330 →
HDAC5 Histone deacetylase 5 0.992 landscape →
Q9BQK8 — 0.990 Q9BQK8 →
Q60700 — 0.990 Q60700 →
O70405 — 0.990 O70405 →
MAP3K9 Mitogen-activated protein kinase kinase kinase 9 0.989 landscape →
Q3ULB5 — 0.989 Q3ULB5 →
Q99P99 — 0.988 Q99P99 →
Q61501 — 0.988 Q61501 →
Q80ZH1 — 0.988 Q80ZH1 →
NR4A1 Nuclear receptor subfamily 4immunitygroup A member 1 0.988 landscape →
Q28969 — 0.988 Q28969 →
Q9TUX8 — 0.988 Q9TUX8 →
Q9Z2V6 — 0.987 Q9Z2V6 →
Q5R902 — 0.987 Q5R902 →
O14512 — 0.987 O14512 →
Q5XIS1 — 0.987 Q5XIS1 →
Q76I79 — 0.987 Q76I79 →
Q6P0Q8 — 0.987 Q6P0Q8 →
Q99PI4 — 0.987 Q99PI4 →
P83038 — 0.987 P83038 →
Q6GQX6 — 0.987 Q6GQX6 →
D3YWQ0 — 0.987 D3YWQ0 →
O09139 — 0.986 O09139 →
Q8TBC3 — 0.986 Q8TBC3 →
P59729 — 0.986 P59729 →
P12813 — 0.986 P12813 →
O89084 — 0.986 O89084 →
Q8BHW9 — 0.986 Q8BHW9 →